Drug intelligence / Profile preview

EgyVax

Development stage: Phase 1
Lead developer: Eva Pharma
Modality: Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

EgyVax is an inactivated whole-virus vaccine developed to provide prophylaxis against COVID-19. It contains killed SARS-CoV-2 virus particles, designed to elicit an immune response without causing disease. The vaccine was developed by EVA Pharma for Pharmaceuticals & Medical Appliances SAE, with manufacturing support from VACSERA (the Holding Company for Biological Products and Vaccines) in Egypt. Preclinical studies demonstrated immunogenicity and safety in animal models, and a phase 1 clinical trial has been conducted to assess its safety and immunogenicity in humans[2][3][7][10]. The vaccine is administered intramuscularly.

Brand names: EgyVax
Other names: EgyVax COVID-19 vaccineEGYVAX

Targets

SARS-CoV-2

Beyond the preview

Go deeper on EgyVax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EgyVax.

Explore the full profile